56 related articles for article (PubMed ID: 1801101)
1. Aromatic ring oxidation of N-n-butylamphetamine is enhanced in the rat by prior treatment with quinidine.
Coutts RT; Baker GB; Malek F; Hussain MS
Res Commun Chem Pathol Pharmacol; 1991 Oct; 74(1):15-24. PubMed ID: 1801101
[TBL] [Abstract][Full Text] [Related]
2. Quinine is a more potent inhibitor than quinidine in rat of the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase.
Muralidharan G; Hawes EM; McKay G; Midha KK
Xenobiotica; 1991 Nov; 21(11):1441-50. PubMed ID: 1763518
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of trimipramine in vitro by human CYP2D6 isozyme.
Bolaji OO; Coutts RT; Baker GB
Res Commun Chem Pathol Pharmacol; 1993 Oct; 82(1):111-20. PubMed ID: 8272570
[TBL] [Abstract][Full Text] [Related]
4. Involvement of CYP2D6 in oxidative metabolism of cinnarizine and flunarizine in human liver microsomes.
Narimatsu S; Kariya S; Isozaki S; Ohmori S; Kitada M; Hosokawa S; Masubuchi Y; Suzuki T
Biochem Biophys Res Commun; 1993 Jun; 193(3):1262-8. PubMed ID: 8323546
[TBL] [Abstract][Full Text] [Related]
5. Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism.
Muralidharan G; Midha KK; McKay G; Hawes EM; Inaba T
Xenobiotica; 1989 Feb; 19(2):189-97. PubMed ID: 2786289
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of methoxyphenamine in vitro by a CYP2D6 microsomal preparation.
Coutts RT; Bolaji OO; Su P; Baker GB
Drug Metab Dispos; 1994; 22(5):756-60. PubMed ID: 7835228
[TBL] [Abstract][Full Text] [Related]
7. Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6.
Young D; Midha KK; Fossler MJ; Hawes EM; Hubbard JW; McKay G; Korchinski ED
Eur J Clin Pharmacol; 1993; 44(5):433-8. PubMed ID: 8359179
[TBL] [Abstract][Full Text] [Related]
8. Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase.
Muralidharan G; Hawes EM; McKay G; Korchinski ED; Midha KK
Eur J Clin Pharmacol; 1991; 41(5):471-4. PubMed ID: 1761076
[TBL] [Abstract][Full Text] [Related]
9. Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans.
Abolfathi Z; Fiset C; Gilbert M; Moerike K; Bélanger PM; Turgeon J
J Pharmacol Exp Ther; 1993 Sep; 266(3):1196-201. PubMed ID: 8371133
[TBL] [Abstract][Full Text] [Related]
10. Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine.
Muralidharan G; Cooper JK; Hawes EM; Korchinski ED; Midha KK
Eur J Clin Pharmacol; 1996; 50(1-2):121-8. PubMed ID: 8739822
[TBL] [Abstract][Full Text] [Related]
11. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.
Otton SV; Brinn RU; Gram LF
Drug Metab Dispos; 1988; 16(1):15-7. PubMed ID: 2894945
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of quinidine and quinine on liver microsome oxidation enzymes in man and rat.
Tu ZG; Zhao LL
Zhongguo Yao Li Xue Bao; 1996 Nov; 17(6):541-4. PubMed ID: 9863152
[TBL] [Abstract][Full Text] [Related]
13. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).
Tyndale RF; Kalow W; Inaba T
Br J Clin Pharmacol; 1991 Jun; 31(6):655-60. PubMed ID: 1867960
[TBL] [Abstract][Full Text] [Related]
14. Metabolic oxidation of carcinogenic arylamines by rat, dog, and human hepatic microsomes and by purified flavin-containing and cytochrome P-450 monooxygenases.
Hammons GJ; Guengerich FP; Weis CC; Beland FA; Kadlubar FF
Cancer Res; 1985 Aug; 45(8):3578-85. PubMed ID: 4016738
[TBL] [Abstract][Full Text] [Related]
15. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis.
Hou ZY; Chen CP; Yang WC; Lai MD; Buchert ET; Chung HM; Pickle LW; Woosley RL
Clin Pharmacol Ther; 1996 Apr; 59(4):411-7. PubMed ID: 8612385
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450-dependent oxidation and glutathione conjugation of xenobiotics in alloxan-induced diabetic rat.
Gupta RR; Agrawal CG; Shukla GS; Ali B
Res Commun Mol Pathol Pharmacol; 1997 Nov; 98(2):231-6. PubMed ID: 9467831
[TBL] [Abstract][Full Text] [Related]
17. The metabolism of tamoxifen by human liver microsomes is not mediated by cytochrome P450IID6.
Blankson EA; Ellis SW; Lennard MS; Tucker GT; Rogers K
Biochem Pharmacol; 1991 Dec; 42 Suppl():S209-12. PubMed ID: 1768279
[No Abstract] [Full Text] [Related]
18. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
[TBL] [Abstract][Full Text] [Related]
19. Oxidation of quinidine by human liver cytochrome P-450.
Guengerich FP; Müller-Enoch D; Blair IA
Mol Pharmacol; 1986 Sep; 30(3):287-95. PubMed ID: 3748010
[TBL] [Abstract][Full Text] [Related]
20. Mechanism-based inactivation of the major beta-naphthoflavone-inducible isozyme of rat liver cytochrome P-450 by the chloramphenicol analog N-(2-p-nitrophenethyl)dichloroacetamide.
Miller NE; Halpert JR
Drug Metab Dispos; 1987; 15(6):846-51. PubMed ID: 2893712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
